Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Therapeutic Areas
Fibromyalgia
Agitation in Alzheimer's Disease
Biodefense
Major Depressive Disorder
Posttraumatic Stress Disorder
Coronavirus Disease 2019 (COVID-19)
Pipeline
Overview
TNX-102 SL for Fibromyalgia
TNX-601 for Major Depressive Disorder (Depression)
TNX-601 for PTSD
TNX-102 SL for AAD
TNX-801 for Biodefense
TNX-1800 (Coronavirus Vaccine)
Scientific Presentations
Expanded Access Policy
News & Events
Press Releases
Tonix In The News
Investor Presentations
IR Events
Investors
Investor Relations
IR Overview
News / Press Releases
News / Press Releases
Press Releases
Tonix In The News
Email Alerts
Presentations & Events
Investor Presentations
IR Events
Multimedia
Multimedia
Financial Info
Financial Info
Financials
Financial Results
SEC Filings
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Fact Sheet
Fact Sheet
Stock Info
Quote
Charts
Historical Data
Analyst Coverage
Governance
Governance
Board of Directors
Board Committees
Governance Documents
Contact
Sign up for Email Alerts
Tonix Pharmaceuticals Holding Corp. on Facebook
Tonix Pharmaceuticals Holding Corp. on Twitter
Tonix Pharmaceuticals Holding Corp. on LinkedIn
Tonix Pharmaceuticals Holding Corp. on Google Plus
Tonix Pharmaceuticals Holding Corp. RSS
Financial Info
: Financial Info
Home
Investors
Financial Info
Investors
Overview
News / Press Releases
Presentations & Events
Multimedia
Financial Info
Financials
Financial Results
SEC Filings
Fact Sheet
Stock Info
Governance
Email Alerts
RSS News Feed
Financial Info
Latest Financial Results
Mar 31, 2020
PDF
HTML
Release
PDF
HTML
10-Q
Filing
HTML
Financials
ZIP
XLS
HTML
XBRL
Latest Annual Report
10-K
Annual report pursuant to Section 13 and 15(d)
March 24, 2020
Financials
View the latest financials
Balance Sheet
Income Statement
Cash Flow
